
    
      The effect of tenofovir on bone mineral density (BMD) has not yet been studied and is of
      potential concern. The purpose of this study is to determine the changes in BMD among
      individuals receiving TDF and FTC/TDF compared with a placebo.

      This substudy will enroll individuals currently participating in MTN-003. The expected
      duration of participation for each participant is approximately 48 months. Study treatment
      will be provided by MTN-003. Study treatment will not be provided by this substudy.

      Study visits will occur every 6 months after enrollment. A nutrition assessment, physical
      activity history, and urine and blood collection will occur at all visits.
    
  